Skip to main content
ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
4.410
-0.170 (-3.71%)
At close: Dec 20, 2024, 4:00 PM
4.190
-0.220 (-4.99%)
After-hours: Dec 20, 2024, 4:34 PM EST

ImmuCell Revenue

ImmuCell had revenue of $6.01M in the quarter ending September 30, 2024, with 11.40% growth. This brings the company's revenue in the last twelve months to $23.84M, up 46.37% year-over-year. In the year 2023, ImmuCell had annual revenue of $17.47M, down -5.90%.

Revenue (ttm)
$23.84M
Revenue Growth
+46.37%
P/S Ratio
1.46
Revenue / Employee
$301,747
Employees
79
Market Cap
39.30M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202317.47M-1.10M-5.90%
Dec 31, 202218.57M-675.01K-3.51%
Dec 31, 202119.24M3.90M25.43%
Dec 31, 202015.34M1.62M11.80%
Dec 31, 201913.72M2.74M24.91%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
DIH Holding US 73.49M
Enzo Biochem 30.31M
CASI Pharmaceuticals 22.06M
OneMedNet 957.65K
CollPlant Biotechnologies 650.00K
Lexaria Bioscience 464.28K
Cardio Diagnostics Holdings 35.69K
Revenue Rankings

ICCC News

More News